Final program
|
November 11th, 2010 |
November 12th, 2010 |
November 13th, 2010 |
||
|
8:00 - 8:30 |
Registration |
|||
|
8:30 - 10:00 |
Opening Remarks (5’) Golden Rules of the two days (5’) Changing epidemiology of fracture (15’) Introduction on FRAX (15’) In patients with RA, how does disease activity, duration or non-glucocorticoid treatment affect fracture probability as estimated by FRAX? (30’) Is there sufficient evidence from recent studies to estimate how dose, type, duration and time from exposure for alcohol & Smoking would impact on fracture probability as estimated by FRAX? (20’) |
Can QUS of the calcaneus be used to assess fracture risk with / without FRAX? (60’) Could the rate of bone loss measured by DXA be used as risk factor for inclusion in FRAX? (30’)
|
||
|
10:00- 10:30 |
Coffee break |
Coffee break |
||
|
10:30- 12:30 |
How does history of falls and frailty affect fracture probability as estimated by FRAX? (20’) How does prior fracture affect fracture probability as estimated by FRAX? (80’) Are bone turnover markers of utility in predicting fracture outcomes? Does it affect fracture probability as estimated by FRAX? (20’) |
Could a clinically useful simplified FRAX model be developed? (60’) How useful is FRAX without BMD? (60’)
|
||
|
12:30- 14:00 |
LUNCH Symposium TERAPIA RANBAXY–EVISTA (Raloxifen) Natural protection in osteoporosis Chair: Catalina Poiana, (RO)
The SERM - an effective and safe medication for the prevention and therapy of osteoporosis. Raloxifen reduces the risk of bone fracture and offers more extraskeletal benefits. By John P. Bilezikian (USA) |
LUNCH Symposium Chair: Ruxandra Maria Ionescu, (RO)
Are all bisphosphonates the same: What makes the difference? By Michael McClung (USA)
|
||
|
14:00- 16:00 |
State of the art lectures Chairpersons: Daniel Grigorie (RO) & Didier Hans (CH) Vertebral fracture: the underestimated phenomenon DXA in the management of osteoporosis: present and future:
|
What guidance can be given to clinicians for how and when to include glucocorticoids as a risk in the FRAX calculations? (90’) Can distal 1/3 radius BMD and/or T-score by DXA be used to assess different fracture risk (15’) Can distal 1/3 radius BMD and/or T-score by DXA be used to assess different fracture risk with FRAX (15’) |
Are the US FRAX Calculators for Blacks, Asians and Hispanics Accurate Enough for Clinical use? (90’) By Jane Cauley (USA)
Are the assumptions used in the FRAX ethnic calculators reasonable given the data available in these populations? (30’)
|
|
|
16:00- 16:15 |
Coffee break |
Coffee break |
Coffee break |
|
|
16:15- 18:15 |
The Epidemiology of Osteonecrosis of the Jaw and Atypical fractures : an Update
By Jane Cauley (USA) Update on vitamin D: skeletal and non-skeletal effects
|
Can lumbar spine BMD and/or T-score be used to assess different fracture risk (30’) Can lumbar spine BMD and/or T-score be used to assess different fracture risk with FRAX (60’) Questions & Answers from the day (30’) |
What should I do if my country doesn't have a FRAX calculator? (90’) By Asma Arabi (LB)
Questions & Answers from the day (30’)
Closing Remarks (5’) |
|
|
18:15- 18:30 |
Registration |
Break |
Break |
|
|
18:30- 22:30 |
Amgen - GSK symposium: Challenges and advances in the treatment of osteoporosis Chairpersons: Socrates Papapoulos (NL) & Corina Galesanu (RO) Introduction (10’) The burden and costs of osteoporosis related fractures (30’) Bone’s structural properties: impact of RANK Ligand inhibition (30’) New clinical evidences for RANK Ligand inhibition in osteoporosis (30’) Discussions (20’) Followed by Dinner |
Servier symposium: Strontium Ranelate: improved bone quality for superior antifracture efficacy Chairpersons: John A. Kanis (UK) & Daniel Grigorie (RO) Introduction (10’) Osteoporosis: better detection for better treatment (30’) Improvement in bone microstructure: an achievable target (30’) “ Strontium Ranelate: clinical antifracture efficacy from FRAX perspective (30’) Discussions (20’) Followed by Dinner |
Social Event Women's Health Gala Dinner |
|
